Nov 04, 2021 / 04:30PM GMT
Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division - Senior Research Analyst
Hi, everybody, and thank you for joining us today. This being the Operational Decisions Conference, we are trying to get to some deep topics, not cover everything but cover a few deep topics. And Lilly's been kind enough to share with us today not 1 but more of the 3 kind of like senior managers with specific topical responsibilities.
So we're going to have to go over the next 45 minutes relatively quickly through discussion with those 3 experts. We have Mark Mintun, which is the Head of R&D in Neurology and Pain and the President of Avid Radiopharm, so he's the man on everything Alzheimer's. We have Jake Van Naarden, who is responsible for Oncology, I guess soups-to-nuts, all the way from R&D to commercial business; and Jamie Croaning, which is responsible for the tirzepatide program. Thank you very much for all 3 of you for joining us today.
Mark A. Mintun - Eli Lilly and Company - Vice-President of Pain & Neurodegeneration Research & Clinical Development<
Eli Lilly and Co at Sanford C Bernstein Operational Decisions Conference Transcript
Nov 04, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers